Abstract
Plasma levels of free and sulfoconjugated 3,4-dihydroxyphenylethyleneglycol (DOPEG), the main deaminated metabolite of norepinephrine, were measured in a group of 45 hospitalized patients presenting a major depression and a group of 45 healthy subjects, matched for sex and age. Compared to healthy subjects, depressed patients had significantly lower plasma levels of free and sulfoconjugated DOPEG. The ratio of free over conjugated DOPEG was not statistically different in the two groups. The reduction of plasma DOPEG levels in the depressed patients did not appear to be related to the duration of drug-free period and was similar in males and females. There was no statistically significant correlation between plasma DOPEG levels and total score on the Hamilton Rating Scale for Depression. Finally, plasma DOPEG levels did not differ in unior bipolar patients. The present data provides further evidence for a reduced CNS noradrenergic transmission in major depression.
Similar content being viewed by others
References
Asberg M, Thoren P, Traskman L, Bertilsson L, Ringberger V (1976) “Serotonin depression”: A biochemical subgroup within the affective disorders? Science 191:478–480
Beckmann H, Goodwin FK (1975) Antidepressant response to triclics and urinary MHPG in unipolar patients. Clinical response to imipramine or amitriptyline. Arch Gen Psychiatry 32:17–21
Beckmann H, Goodwin FK (1980) Urinary MHPG in subgroups of depressed patients and normal controls. Neuropsychobiology 6:91–100
Berger PA, Faull KF, Kilkowski J, Anderson PJ, Kraemer H, Davis K, Barchas JD (1980) CSF monoamine metabolites in depression and schizophrenia. Am J Psychiatry 137:174–180
Bunney WE Jr, Davis JM (1965) Norepinephrine in depressive reactions. Arch Gen Psychiatry 13:483–494
Carroll BJ, Feinberg M, Greden JF, Tarika J, Albala AA (1981) A specific laboratory test for the diagnosis of melancholia. Standardization, validation and clinical utility. Arch Gen Psychiatry 38:15–22
Coppen A, Prange AJ, Whybrow PC, Hill C, Noguera R (1972) Abnormalities of indoleamines in affective disorders. Arch Gen Psychiatry 26:474–478
Crawley JN, Hattox SE, Maas JW, Roth RH (1978) 3-Methoxy-4-hydroxyphenylethyleneglycol increase in plasma after stimulation of the nucleus locus coeruleus. Brain Res 141:380–384
Dennis T, Scatton B (1982) A radioenzymatic technique for the measurement of free and conjugated 3,4-dihydroxyphenylethyleneglycol in brain tissue and biological fluids. J Neurosci Methods 6:369–382
Domino EF, Dren AT, Giardina WJ (1978) Biochemical and neurotransmitter change in the aging brain. In: Lipton MA, Di Mascio A, Killam FK (eds) Psychopharmacology: A generation of progress, New York, Raven Press, pp 1507–1515
Edwards DJ, Spiker DG, Neil JF, Kupfer DJ, Rizk M (1980) MHPG excretion in depression. Psychiatr Res 2:295–305
Elsworth JD, Redmond DE Jr, Roth RH (1982) Plasma and cerebrospinal fluid 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) as indices of brain norepinephrine metabolism in primates. Brain Res 225:115–124
Garver DL, Davis JM (1979) Biogenic amine hypotheses of affective disorders. Life Sci 24:383–394
Goodwin FK, Post RM, Dunner DL, Gordon EK (1973) Cerebrospinal fluid amine metabolites in affective illness: the probenecid technique. Am J Psychiatry 130:73–79
Goodwin FK, Wirz-Justice A, Wehr TA (1982) Evidence that the pathophysiology of depression and the mechanism of action of antidepressant drugs both involve alterations in circadian rhythms. Adv Biochem Psychopharmacol 32:1–11
Gorden EK, Oliver J (1971) 3-Methoxy-4-hydroxy phenylethylene glycol in human CSF. Clin Chim Acta 35:145–150
Hamilton M (1967) The development of rating scale of depression. Brit J Soc Clin Psychol 6:278–296
Hollister LE, Davis KL, Overall JE, Anderson T (1978) Excretion of MHPG in normal subjects. Implications for biological classification of affective disorders. Arch Gen Psychiat 35:1410–1415
Hollister LE, Davis KL, Berger PA (1980) Subtypes of depression based on excretion of MHPG and response to nortriptyline. Arch Gen Psychiatry 37:1107–1110
Huff JW, Reigle TG (1980) Effects of morphine and other centrally actings drugs on 3,4-dihydroxyphenylethyleneglycol (DOPEGSO4) in rat brain. Life Sci 27:1483–1488
Koester G, Breuer H, Schneider HT (1982) Effect of 2 substituted estrogens in vivo on the metabolism of noradrenaline in the rat brain. Acta Endocrinol 99:1–8
Kopin IJ, Gordon EK, Jimerson DC, Polinsky RJ (1982) Relation between plasma and cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylglycol Science 219:73–75
Koslow SH, Maas JW, Bowden CL, Davis JM, Hanin I, Javaid J (1983) CSF and urinary biogenic amines and metabolites in depression and mania. Arch Gen Psychiatry 40:999–1010
Loo H, Zarifian E (1982) Abord critique des facteurs biochimiques au cours des syndromes dépressifs et prescription d'antidépresseurs. Ann Médicopsychol 140:240–250
Loo H, Scatton B, Le Fur G, Gay C, Benkelfat C, Susini-Deluca H, Poirier MF, Olié JP, Askienazy S (1984) Place of indalpine in psychiatric treatment. Adv Biol Psychiat 14:76–85
Maas JW (1975) Biogenic amines and depression. Arch Gen Psychiatry 32:1357–1364
Maas JW (1978) Clinical and biochemical heterogeneity of depressive disorders. Ann Int Med 88:556–563
Maas JW, Fawcett J, Dekirmenjian H (1968) 3-Methoxy-4-hydroxyphenylglycol (MHPG) excretion in depressive states: a pilot study. Arch Gen Psychiatry 19:129–134
Pickar D, Sweeney DR, Maas JW, Heninger GR (1978) Primary affective disorder, clinical state change, and MHPG excretion: A longitudinal study. Arch Gen Psychiatry 35:1378–1383
Post RM, Gordon EK, Goodwin FK, Bunney WE (1973) Central norepinephrine metabolism in affective illness: MHPG in the CSF. Science 179:1002–1003
Ramon De La Fuente J, Rosenbaum AH (1978) Clinical and neuroendocrine correlates of elevated platelet M.A.O. activity. Am J Psychiatry 135:994
Robinson DS, Johnson GA, Nies A, Corcella J, Cooper TB, Albright D, Howard D (1983) Plasma levels of catecholamines and dihydroxyphenylglycol during antidepressant drug treatment. J Clin Psychopharmacol 3:282–287
Rosenbaum AM, Schatzberg AF, Maruta T, Orsulak PJ, Cole JO, Grab EL, Schildkraut JJ (1980) MHPG as a predictor of antidepressant response to imipramine and maprotiline. Am J Psychiatry 137:1090–1092
Sachar EJ (1975) Neuroendocrine dysfunction in depressive illness. Ann Rev Med 27:389–396
Scatton B (1982) Brain 3,4-dihydroxyphenylethyleneglycol levels are dependent on central noradrenergic neuron activity. Life Sci 31:495–504
Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122:509–522
Schildkraut JJ (1973) Norepinephrine metabolites as biochemical criteria for classifying depressive disorders and predicting responses to treatment: preliminary findings. Am J Psychiatry 130:695–698
Schildkraut JJ, Orsulak PJ, Schatzberg AF, Gudeman JE, Cole JO, Rohde WA, La Brie RA (1978) Toward a biochemical classification of depressive disorders. I. Differences in urinary excretion of MHPG and other catecholamine metabolites in clinically defined subtypes of depression. Arch Gen Psychiatry 35:1427–1433
Schlesser MA, Winokur G, Sherman BM (1980) Hypothalamicpituitary-adrenal axis activity in depressive illness. Its relationship to classification. Arch Gen Psychiatry 37:737–743
Shaw DM, O'Keeffe R, MacSweeney DA, Brooksbank BW, Noguera R, Coppen A (1973) 3-Methoxy-4-hydroxyphenylglycol in depression. Psychol Med 3:333–336
Subrahmanyam S (1975) Role of biogenic amines in certain pathological conditions. Brain Res 87:355–362
Van Praag HM (1977) Significance of biochemical parameters in the diagnosis, treatment and prevention of depressive disorders. Biol Psychiatry 12:101–131
Van Praag HM, Korf J, Schut D (1973) Cerebral monoamines and depression: an investigation with the probenecid technique. Arch Gen Psychiatry 28:827–831
Vestergaard P, Sorensen T, Hoppe E, Rafaelsen OJ, Yates CM, Nicolaou N (1978) Biogenic amine metabolites in cerebrospinal fluid of patients with affective disorders. Acta Psychiatr Scand 58:88–96
Wehr TA, Wirz-Justice A (1982) Circadian rhythm mechanisms in affective illness and in antidepressant drug action. Pharmacopsychiatria 15:31–39
Wilk S, Shopsin B, Gershon S, Suhl M (1972) Cerebrospinal fluid levels of MHPG in affective disorders. Nature 235:440–441
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scatton, B., Loo, H., Dennis, T. et al. Decrease in plasma levels of 3,4-dihydroxyphenylethyleneglycol in major depression. Psychopharmacologia 88, 220–225 (1986). https://doi.org/10.1007/BF00652244
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00652244